Drug Trial Radar · NCT03737643
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients
Last checked: Nov 19, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,407
Actual
Start
Jan 4, 2019
Primary completion
Mar 17, 2025
Study completion Dec 23, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation; Myriad Genetic Laboratories, Inc.
- First posted
- Nov 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase III randomised, double-blind, multi-centre study to evaluate the efficacy and safety of durvalumab in combination with standard of care platinum based chemotherapy and bevacizumab followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian cancer.
Conditions
- Advanced Ovarian Cancer
Interventions
BevacizumabDrug
Bevacizumab by intravenous infusion. In tBRCAm cohort bevacizumab is optional according to local practice.
DurvalumabDrug
Durvalumab by intravenous infusion
OlaparibDrug
Olaparib tablets
Placebo olaparibDrug
Placebo tablets to match olaparib
Durvalumab placeboDrug
Matching placebo for intravenous infusion
Carboplatin+PaclitaxelDrug
Standard of care chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - Full Analysis SetTime frame: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Assessed until primary analysis - (05DEC2022 for Global cohort, 17MAR2025 for China cohort) - upto 46 months
- Progression-free Survival (PFS) by Investigator Assessment Using Modified RECIST 1.1 - (Full Analysis Set, HRD Positive)Time frame: At baseline, within 3 weeks of last dose of chemotherapy, then every 12 weeks for 3 years and thereafter every 24 weeks. Assessed until DCO1 - (05DEC2022 for Global cohort, 17MAR2025 for China cohort) - upto 46 months
Locations
214 sites in 20 countries. Site status is shown where the registry gives one.
Research Site
Foothill Ranch, California
Research Site
Los Angeles, California
Research Site
Orange, California
Research Site
San Francisco, California
Research Site
Tampa, Florida
Research Site
Augusta, Georgia
Research Site
Hinsdale, Illinois
Research Site
Indianapolis, Indiana
Research Site
Towson, Maryland
Research Site
Detroit, Michigan
Research Site
Springfield, Missouri
Research Site
Middletown, New Jersey
Research Site
Montvale, New Jersey
Research Site
Albany, New York
Research Site
New York, New York
Research Site
Uniondale, New York
Research Site
Durham, North Carolina
Research Site
Cleveland, Ohio
Research Site
Dayton, Ohio
Research Site
Hilliard, Ohio
Research Site
Tulsa, Oklahoma
Research Site
Lancaster, Pennsylvania
Research Site
Philadelphia, Pennsylvania
Research Site
Philadelphia, Pennsylvania
Research Site
Pittsburgh, Pennsylvania
Research Site
Salt Lake City, Utah
Research Site
Graz, Austria
Research Site
Innsbruck, Austria
Research Site
Linz, Austria
Research Site
Vienna, Austria
Research Site
Aalst, Belgium
Research Site
Leuven, Belgium
Research Site
Namur, Belgium
Research Site
Ostend, Belgium
Research Site
Sint-Niklaas, Belgium
Research Site
Barretos, Brazil
Research Site
Florianópolis, Brazil
Research Site
Fortaleza, Brazil
Research Site
Londrina, Brazil
Research Site
Porto Alegre, Brazil
Showing 40 of 214 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.